Here, we found that PRKDC mutation often co‐exists with other DNA damage repair deficiencies and is associated with an increased tumor mutation burden, an inflamed tumor microenvironment, and a good response to immune checkpoint inhibitors. This evidence concerns the gene PRKDC and neoplasm.